Загрузка...
An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of...
Сохранить в:
| Опубликовано в: : | Chest |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American College of Chest Physicians
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5991580/ https://ncbi.nlm.nih.gov/pubmed/23648912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1378/chest.12-1604 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|